Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

360 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes.
Guo L, Parker DL, Zang Y, Sweis RF, Liu W, Sherer EC, Buist N, Terebetski J, Kelly T, Bugianesi R, Priest BT, Dingley KH, Li X, Mitelman S, Salituro G, Trujillo ME, Pachanski M, Kirkland M, Powles MA, Eiermann GJ, Feng Y, Shang J, Howard AD, Ujjainwalla F, Sinz CJ, Debenham JS, Edmondson SD, Nargund RP, Hagmann WK, Li D. Guo L, et al. Among authors: parker dl. ACS Med Chem Lett. 2016 Oct 12;7(12):1107-1111. doi: 10.1021/acsmedchemlett.6b00314. eCollection 2016 Dec 8. ACS Med Chem Lett. 2016. PMID: 27994747 Free PMC article.
Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes.
Wilson JE, Kurukulasuriya R, Sinz C, Lombardo M, Bender K, Parker D, Sherer EC, Costa M, Dingley K, Li X, Mitelman S, Tong S, Bugianesi R, Ehrhardt A, Priest B, Ratliff K, Ujjainwalla F, Nargund R, Hagmann WK, Edmondson S. Wilson JE, et al. Bioorg Med Chem Lett. 2016 Jun 15;26(12):2947-2951. doi: 10.1016/j.bmcl.2016.04.018. Bioorg Med Chem Lett. 2016. PMID: 27240550
Development of a novel class of potent and selective FIXa inhibitors.
Zhang T, Andre P, Bateman TJ, Chen YH, Desai K, Ellsworth K, Geissler WM, Guo L, Hruza A, Jian T, Meng D, Parker DL Jr, Qian X, Reichert P, Sherer EC, Shu M, Smith CJ, Sonatore LM, Tschirret-Guth R, Nolting AF, Orr R, Campeau LC, Araki K, Nishimura T, Sakurada I, Wood HB. Zhang T, et al. Among authors: parker dl jr. Bioorg Med Chem Lett. 2015 Nov 1;25(21):4945-4949. doi: 10.1016/j.bmcl.2015.04.057. Epub 2015 Apr 29. Bioorg Med Chem Lett. 2015. PMID: 25978966
Rapid development of two factor IXa inhibitors from hit to lead.
Parker DL Jr, Walsh S, Li B, Kim E, Sharipour A, Smith C, Chen YH, Berger R, Harper B, Zhang T, Park M, Shu M, Wu J, Xu J, Dewnani S, Sherer EC, Hruza A, Reichert P, Geissler W, Sonatore L, Ellsworth K, Balkovec J, Greenlee W, Wood HB. Parker DL Jr, et al. Bioorg Med Chem Lett. 2015 Jun 1;25(11):2321-5. doi: 10.1016/j.bmcl.2015.04.025. Epub 2015 Apr 13. Bioorg Med Chem Lett. 2015. PMID: 25937013
Development of a novel tricyclic class of potent and selective FIXa inhibitors.
Meng D, Andre P, Bateman TJ, Berger R, Chen YH, Desai K, Dewnani S, Ellsworth K, Feng D, Geissler WM, Guo L, Hruza A, Jian T, Li H, Metzger J, Parker DL, Reichert P, Sherer EC, Smith CJ, Sonatore LM, Tschirret-Guth R, Wu J, Xu J, Zhang T, Campeau LC, Orr R, Poirier M, McCabe-Dunn J, Araki K, Nishimura T, Sakurada I, Hirabayashi T, Wood HB. Meng D, et al. Among authors: parker dl. Bioorg Med Chem Lett. 2015 Nov 15;25(22):5437-43. doi: 10.1016/j.bmcl.2015.07.078. Epub 2015 Jul 31. Bioorg Med Chem Lett. 2015. PMID: 26318999
Triazolo-tetrahydrofluorenones as selective estrogen receptor beta agonists.
Parker DL Jr, Meng D, Ratcliffe RW, Wilkening RR, Sperbeck DM, Greenlee ML, Colwell LF, Lambert S, Birzin ET, Frisch K, Rohrer SP, Nilsson S, Thorsell AG, Hammond ML. Parker DL Jr, et al. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4652-6. doi: 10.1016/j.bmcl.2006.05.103. Epub 2006 Jun 13. Bioorg Med Chem Lett. 2006. PMID: 16777408
Synthesis and properties of 2-(naphthosultamyl)methyl-carbapenems with potent anti-MRSA activity: discovery of L-786,392.
Ratcliffe RW, Wilkening RR, Wildonger KJ, Waddell ST, Santorelli GM, Parker DL Jr, Morgan JD, Blizzard TA, Hammond ML, Heck JV, Huber J, Kohler J, Dorso KL, St Rose E, Sundelof JG, May WJ, Hammond GG. Ratcliffe RW, et al. Among authors: parker dl jr. Bioorg Med Chem Lett. 1999 Mar 8;9(5):679-84. doi: 10.1016/s0960-894x(99)00071-2. Bioorg Med Chem Lett. 1999. PMID: 10201828
Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
Apgar JM, Wilkening RR, Parker DL Jr, Meng D, Wildonger KJ, Sperbeck D, Greenlee ML, Balkovec JM, Flattery AM, Abruzzo GK, Galgoci AM, Giacobbe RA, Gill CJ, Hsu MJ, Liberator P, Misura AS, Motyl M, Nielsen Kahn J, Powles M, Racine F, Dragovic J, Fan W, Kirwan R, Lee S, Liu H, Mamai A, Nelson K, Peel M. Apgar JM, et al. Among authors: parker dl jr. Bioorg Med Chem Lett. 2021 Jan 15;32:127661. doi: 10.1016/j.bmcl.2020.127661. Epub 2020 Nov 4. Bioorg Med Chem Lett. 2021. PMID: 33160023
MK-5204: An orally active β-1,3-glucan synthesis inhibitor.
Apgar JM, Wilkening RR, Parker DL Jr, Meng D, Wildonger KJ, Sperbeck D, Greenlee ML, Balkovec JM, Flattery AM, Abruzzo GK, Galgoci AM, Giacobbe RA, Gill CJ, Hsu MJ, Liberator P, Misura AS, Motyl M, Kahn JN, Powles M, Racine F, Dragovic J, Fan W, Kirwan R, Lee S, Liu H, Mamai A, Nelson K, Peel M. Apgar JM, et al. Among authors: parker dl jr. Bioorg Med Chem Lett. 2020 Sep 1;30(17):127357. doi: 10.1016/j.bmcl.2020.127357. Epub 2020 Jun 19. Bioorg Med Chem Lett. 2020. PMID: 32738971
360 results